PARIS, Dec 4 (Reuters) - Sanofi-Aventis (SASY.PA) plans to cut its U.S. sales force by up to 10 percent as it prunes costs in the face of price pressure, a spokesman said on Thursday.
“The process is underway,” adding the world’s fourth-largest drugs group was adapting to “changes taking place on the U.S. market.”
Chris Viehbacher started as new CEO at Sanofi-Aventis on Monday. The French group employs some 6,500 sales staff in the U.S. and rivals are also shedding jobs.
In the past two years Sanofi has been gradually scrapping jobs in North America and Europe where several of its best-selling drugs, such as blood thinners Lovenox and Plavix and cancer treatment Eloxatin, are being challenged by drugmakers seeking to sell cheaper copies.
Like many of its competitors, Sanofi faces pressure on prices of its drugs while its drug development pipeline has yet to produce new medicines viable for marketing. (Reporting by Noelle Mennella; Editing by Hans Peters)